Zanzalintinib plus Tecentriq significantly improved overall survival versus Stivarga in previously treated metastatic ...

By sharing her own experiences and helping athletes see their value, Anne has truly become the ultimate “coach.” When she ...

Colorectal cancer (CRC) is the second most common cause of death from cancer in the US and the most prevalent malignant tumor ...

UCLA scientists have uncovered a surprising survival strategy in cells, especially cancer cells, that may help explain how ...

Shares of Exelixis, Inc. EXEL gained 7.4% on June 23, after the company announced positive top-line results from the ...

Colorectal cancer (CRC) is the second most common cause of death from cancer in the United States (US) and the most prevalent ...

In combination with Roche’s PD-L1 blocker Tecentriq, zanzalintinib bested Bayer’s Stivarga. Exelixis is positioning the drug ...

New trial results reveal zanzalintinib and atezolizumab significantly enhance survival in metastatic colorectal cancer, ...

Top-line results from a Phase III trial showed an overall survival benefit for zanzalintinib combo therapy in microsatellite-stable colorectal cancer.

Colorectal cancer highlights from ASCO 2025 include findings from the BREAKWATER, ATOMIC, DYNAMIC-III, and TRIPLETE trials.

Exelixis' STELLAR-303 trial shows zanzalintinib plus Tecentriq improved survival in colorectal cancer, with no new safety ...